ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

ClinicalTrials.gov ID: NCT04858256

Public ClinicalTrials.gov record NCT04858256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Study identification

NCT ID
NCT04858256
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Enrollment
100 participants

Conditions and interventions

Interventions

  • Pacritinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 28, 2023
Primary completion
Oct 31, 2027
Completion
Oct 31, 2028
Last update posted
Jan 28, 2026

2023 – 2028

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
City of Hope Duarte California 91010 Recruiting
Moffitt Cancer Center Tampa Florida 33612 Not yet recruiting
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 Recruiting
Duke Cancer Institute Durham North Carolina 27710 Recruiting
Ohio State University Comprehensive Cancer Center Columbus Ohio 43202 Recruiting
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04858256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 28, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04858256 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →